Cabozantinib boosts survival for some patients with RET+ medullary thyroid cancer

LAKE BUENA VISTA, Fla. – The tyrosine kinase inhibitor cabozantinib significantly extended overall survival for patients with RET-M918T–positive medullary thyroid cancer.

The placebo-controlled EXAM...